Improving Office Based Treatment of Opioid Use Disorder With Technology

• Status: Unknown status
• Trial end date: 2020-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this study is to evaluate whether using a novel drug-device combination to deliver buprenorphine/naloxone (B/N) to patients in office-based treatment for Opioid Use Disorder (OUD) is an effective way to improve compliance and treatment outcomes. The system introduces psychological and behavioral supports in addition to securing the medication between doses.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: MedicaSafe, Inc.
• Collaborators: Artemis Institute for Clinical Research; Friends Research Institute, Inc.; Total Health Care
• Treatments: Analgesics, Opioid; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Naloxone

Criteria

Inclusion Criteria:

• Be between the ages of 18 and 65 years old

• Be able to provide informed consent

• Be English-speaking

• Have consistent phone and/or internet access

• Deemed by physician as medically, psychiatrically, and otherwise appropriate for buprenorphine therapy

• Maintained on a stable B/N dose

Exclusion Criteria:

• Be younger than 18 or older than 65 years of age

• Chronic pain

• Be non-English speaking

• Be unable to complete informed consent

• Be pregnant